Previous 10 | Next 10 |
Neurocrine Biosciences ' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. The stock was up around 15% as of the market close on Monday. But Neurocrine's shares are now likely to go even higher. The biotech announc...
Neurocrine Biosciences, Inc. (NBIX) Q2 2020 Results Conference Call August 03, 2020 04:30 PM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO Matt Abernethy - CFO Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief ...
Neurocrine Biosciences (NASDAQ: NBIX ) Q2 results : More news on: Neurocrine Biosciences, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Neurocrine Biosciences (NASDAQ: NBIX ) : Q2 Non-GAAP EPS of $1.42 beats by $0.40 ; GAAP EPS of $0.81 beats by $0.15 . Revenue of $302.4M (+64.7% Y/Y) beats by $40.74M . Press Release More news on: Neurocrine Biosciences, Inc., Earnings news and commentary, Healthcare stocks news,...
SAN DIEGO , Aug. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2020 and provided revised full-year 2020 financial expense guidance. "I want to thank healthcare providers and o...
SAN DIEGO , July 30, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday , August 6, 2020. Kyle Gano , Chief Business Development and Strategy Officer, will participate in a pan...
In July 16, 2019, I shared my first Seeking Alpha article related to Idorsia ( IDRSF ), a Swiss based biotech with an illustrious history for discovering new drugs and shepherding them through the FDA approval process. This is a link for my original article that outlines the backstory for ho...
Neurocrine Biosciences (NASDAQ: NBIX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Neurocrine has announced a list price of $590 for a 30-count bottle of their new product Ongentys for the adjunctive treatment of Parkinson's ...
SAN DIEGO , July 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, August 3, 2020 . Neurocrine will then host a conference call and webcast to discuss its fin...
Eli Lilly & Co. (LLY), AbbVie Inc. (ABBV), Zoetis Inc. (ZTS) and Neurocrine Biosciences Inc. (NBIX) are stocks that could move significantly higher in the second half of this year. Pharmaceutical stocks have been soaring in the past couple of months. Many are nearing their 52-wee...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...